ico therapeutics inc (ICOTF:OTC US)
ico therapeutics inc (ICOTF) Snapshot
|
Open
$0.32
|
Previous Close
$0.33
|
|
|
Day High
$0.33
|
Day Low
$0.32
|
|
|
52 Week High
12/27/12 - $0.87
|
52 Week Low
05/31/12 - $0.29
|
|
|
Market Cap
--
|
Average Volume 10 Days
6.2K
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
ico therapeutics inc (ICOTF) Related Businessweek News
No Related Businessweek News Foundico therapeutics inc (ICOTF) Details
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed drug candidates include iCo-007, an anti-sense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; iCo-008 (Bertilimumab), a monoclonal antibody, which is in Phase II clinical trial to treat patients with moderate-to-severe ulcerative colitis; and iCo-009, an experimental oral formulation of Amphotericin B that is in pre-clinical stage for the treatment of systemic fungal infections and parasitical infections. The company has partnership arrangements with Isis Pharmaceuticals Inc. to develop and commercialize iCo-007; MedImmune Limited and Immune Pharmaceuticals Corp. to develop and commercialize iCo-008; and the University of British Columbia for the development of iCo-009, as well as a research collaboration agreement with Juvenile Diabetes Research Foundation (JDRF) to support the Phase II clinical trial of iCo-007. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
ico therapeutics inc (ICOTF) Top Compensated Officers
ico therapeutics inc (ICOTF) Key Developments
iCo Therapeutics Inc. Presents at Bloom Burton & Co Healthcare Investor Conference, May-22-2013 02:00 PM. Venue: Toronto Board of Trade, 1 First Canadian Place, Toronto, ON M5X 1C1, Canada.
iCo Therapeutics Inc. reported earnings results for the year ended December 31, 2012. For the year, the company reported net and comprehensive loss of CAD 3,430,427 compared to a net and comprehensive loss of CAD 993,491 for the year ended 2011, representing an increase of CAD 2,436,936. The increase in net and comprehensive loss was principally caused by clinical trial costs associated with iCo-007.
iCo Therapeutics Inc. filed its Annual on Apr 25, 2013 for the period ending Dec 31, 2012. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
| Recently Viewed | |||
| ICOTF:US | $0.33 USD | 0.00 |  |
| Company | Last | Change | |
| No competitor information is available for ICOTF. | |||
| View Industry Companies | |||
Industry Analysis
ICOTF
Industry Average
| Valuation | ICOTF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 8.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ICO THERAPEUTICS INC, please visit www.icotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
